Ivy Lai
Overview
Explore the profile of Ivy Lai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zamler D, Shingu T, Kahn L, Huntoon K, Kassab C, Ott M, et al.
JCI Insight
. 2022 Jun;
7(12).
PMID: 35653194
Novel therapeutic strategies targeting glioblastoma (GBM) often fail in the clinic, partly because preclinical models in which hypotheses are being tested do not recapitulate human disease. To address this challenge,...
2.
Pan K, Chiu Y, Huang E, Chen M, Wang J, Lai I, et al.
Proc Natl Acad Sci U S A
. 2021 Nov;
118(46).
PMID: 34725257
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections elicit both humoral and cellular immune responses. For the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2, it has become...
3.
Pan K, Chiu Y, Huang E, Chen M, Wang J, Lai I, et al.
bioRxiv
. 2021 Jul;
PMID: 34312620
Significance Statement: Current state of the art uses putative epitope peptides based on prediction algorithms to evaluate the T cell response among COVID-19 patients. However, none of these peptides have...
4.
Pan K, Chiu Y, Chen M, Wang J, Lai I, Singh S, et al.
bioRxiv
. 2021 Jul;
PMID: 34268504
SARS-CoV-2 infections elicit both humoral and cellular immune responses. For the prevention and treatment of COVID19, the disease caused by SARS-CoV-2, it has become increasingly apparent that T cell responses...
5.
Bradley S, Talukder A, Lai I, Davis R, Alvarez H, Tiriac H, et al.
Nat Commun
. 2020 Oct;
11(1):5332.
PMID: 33087697
Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for inducing clinical regressions by targeting tumor-associated antigens (TAA). To expand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we...
6.
Chapuis A, Desmarais C, Emerson R, Schmitt T, Shibuya K, Lai I, et al.
Sci Immunol
. 2017 Apr;
2(8).
PMID: 28367538
Adoptively transferred tumor-specific cells can mediate tumor regression in cancers refractory to conventional therapy. Autologous polyclonal tumor-specific cytotoxic T cells (CTL) generated from peripheral blood and infused into patients with...
7.
Chapuis A, Lee S, Thompson J, Roberts I, Margolin K, Bhatia S, et al.
J Exp Med
. 2016 Jun;
213(7):1133-9.
PMID: 27242164
Adoptive transfer of peripheral blood-derived, melanoma-reactive CD8(+) cytotoxic T lymphocytes (CTLs) alone is generally insufficient to eliminate bulky tumors. Similarly, monotherapy with anti-CTLA4 infrequently yields sustained remissions in patients with...
8.
Chapuis A, Afanasiev O, Iyer J, Paulson K, Parvathaneni U, Hwang J, et al.
Cancer Immunol Res
. 2014 Jan;
2(1):27-36.
PMID: 24432305
Merkel cell carcinoma (MCC) is an aggressive skin cancer that typically requires the persistent expression of Merkel cell polyomavirus (MCPyV) oncoproteins that can serve as ideal immunotherapeutic targets. Several immune...
9.
Iyer J, Afanasiev O, McClurkan C, Paulson K, Nagase K, Jing L, et al.
Clin Cancer Res
. 2011 Sep;
17(21):6671-80.
PMID: 21908576
Purpose: Merkel cell polyomavirus (MCPyV) is prevalent in the general population, integrates into most Merkel cell carcinomas (MCC), and encodes oncoproteins required for MCC tumor growth. We sought to characterize...